A systematic evidence-based review of treatments for primary hyperhidrosis

References

• Doolittle J, Walker P, Mills T, et al. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res. 2016;308(10):743–749.
   PubMed Web of Science ®Google Scholar
• Glaser DA, Hebert A, Pieretti L, et al. Understanding patient experience with hyperhidrosis: a national survey of 1,985 patients. J Drugs Dermatol. 2018;17(4):392–396.
   PubMed Web of Science ®Google Scholar
• Hamm H, Naumann MK, Kowalski JW, et al. Primary focal hyperhidrosis: disease characteristics and functional impairment. Dermatology. 2006;212(4):343–353.
   PubMed Web of Science ®Google Scholar
• Naumann MK, Hamm H, Lowe NJ. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol. 2002;147(6):1218–1226.
   PubMed Web of Science ®Google Scholar
• Kamudoni P, Mueller B, Halford J, et al. The impact of hyperhidrosis on patients’ daily life and quality of life: a qualitative investigation. Health Qual Life Outcomes. 2017;15(1):121.
   PubMed Web of Science ®Google Scholar
• Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: a comprehensive review: therapeutic options. J Am Acad Dermatol. 2019;81(3):669–680.
   PubMed Web of Science ®Google Scholar
• QBREXZA® (glycopyrronium) cloth [prescribing information]. Menlo Park (CA): Dermira Inc.; 2018. Available from: http://pi.dermira.com/QbrexzaPI.pdf
   Google Scholar
• BOTOX® (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use [prescribing information]. Irvine (CA): Allergan, Inc.; 2011. Available from: https://media.allergan.com/actavis/actavis/media/allergan-pdf-documents/product-prescribing/20190620-BOTOX-100-and-200-Units-v3-0USPI1145-v2-0MG1145.pdf
   Google Scholar
• Wechter T, Feldman SR, Taylor SL. The treatment of primary focal hyperhidrosis. Skin Therapy Lett. 2019;24(1):1–7.
   Google Scholar
• Ioannidis JPA, Stuart ME, Brownlee S, et al. How to survive the medical misinformation mess. Eur J Clin Invest. 2017;47(11):795–802.
   PubMed Web of Science ®Google Scholar
• Wade R, Rice S, Llewellyn A, et al. Interventions for hyperhidrosis in secondary care: a systematic review and value-of-information analysis. Health Technol Assess. 2017;21(80):1–280.
   PubMed Web of Science ®Google Scholar
• Wade R, Llewellyn A, Jones-Diette J, et al. Interventional management of hyperhidrosis in secondary care: a systematic review. Br J Dermatol. 2018;179(3):599–608.
   PubMed Web of Science ®Google Scholar
• PICO annotation; 2020; [cited 2020 Jun 30]. Available from: https://training.cochrane.org/resource/cochrane-information-specialists-handbook/12-pico-annotation
   Google Scholar
• Collaboration TC. Methodological expectations of Cochrane Intervention Reviews (MECIR): standards for the reporting of plain language summaries in new Cochrane Intervention Reviews; version 1; 2013; [cited 2019 Aug 22]. Available from: https://methods.cochrane.org/sites/default/files/public/uploads/pleacs_2019.pdf
   Google Scholar
• Glasziou P, Chalmers I, Rawlins M, et al. When are randomised trials unnecessary? Picking signal from noise. BMJ. 2007;334(7589):349–351.
   PubMed Web of Science ®Google Scholar
• Glaser DA, Hebert AA, Nast A, et al. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2019;80(1):128–138e2.
   PubMed Web of Science ®Google Scholar
• Heckmann M, Ceballos-Baumann AO, Plewig G. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med. 2001;344(7):488–493.
   PubMed Web of Science ®Google Scholar
• Flanagan KH, Glaser DA. An open-label trial of the efficacy of 15% aluminum chloride in 2% salicylic acid gel base in the treatment of moderate-to-severe primary axillary hyperhidrosis. J Drugs Dermatol. 2009;8(5):477–480.
   PubMed Web of Science ®Google Scholar
• Flanagan KH, King R, Glaser DA. Botulinum toxin type a versus topical 20% aluminum chloride for the treatment of moderate to severe primary focal axillary hyperhidrosis. J Drugs Dermatol. 2008;7(3):221–227.
   PubMed Web of Science ®Google Scholar
• Glaser DA, Hebert AA, Nast A, et al. A 44-week open-label study evaluating safety and efficacy of topical glycopyrronium tosylate in patients with primary axillary hyperhidrosis. Am J Clin Dermatol. 2019;20(4):593–604.
   PubMed Web of Science ®Google Scholar
• Goh CL. Aluminum chloride hexahydrate versus palmar hyperhidrosis. Evaporimeter assessment. Int J Dermatol. 1990;29(5):368–370.
   PubMed Web of Science ®Google Scholar
• Scholes KT, Crow KD, Ellis JP, et al. Axillary hyperhidrosis treated with alcoholic solution of aluminium chloride hexahydrate. Br Med J. 1978;2(6130):84–85.
   PubMedGoogle Scholar
• Artzi O, Loizides C, Zur E, et al. Topical oxybutynin 10% gel for the treatment of primary focal hyperhidrosis: a randomized double-blind placebo-controlled split area study. Acta Derm Venereol. 2017;97(9):1120–1124.
   PubMed Web of Science ®Google Scholar
• Hyun MY, Son IP, Lee Y, et al. Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: a randomized, multicentre, double-blinded, placebo-controlled, split-face study. J Eur Acad Dermatol Venereol. 2015;29(2):278–282.
   PubMed Web of Science ®Google Scholar
• Budamakuntla L, Loganathan E, George A, et al. Comparative study of efficacy and safety of botulinum toxin a injections and subcutaneous curettage in the treatment of axillary hyperhidrosis. J Cutan Aesthet Surg. 2017;10(1):33–39.
   PubMedGoogle Scholar
• Lueangarun S, Sermsilp C, Tempark T. Topical botulinum toxin type a liposomal cream for primary axillary hyperhidrosis: a double-blind, randomized, split-site, vehicle-controlled study. Dermatol Surg. 2018;44(8):1094–1101.
   PubMed Web of Science ®Google Scholar
• Montaser-Kouhsari L, Zartab H, Fanian F, et al. Comparison of intradermal injection with iontophoresis of abobotulinum toxin A for the treatment of primary axillary hyperhidrosis: a randomized, controlled trial. J Dermatolog Treat. 2014;25(4):337–341.
   PubMed Web of Science ®Google Scholar
• Glogau RG. Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study. Dermatol Surg. 2007;33(s1):S76–S80.
   PubMedGoogle Scholar
• Ibrahim O, Kakar R, Bolotin D, et al. The comparative effectiveness of suction-curettage and onabotulinumtoxin-A injections for the treatment of primary focal axillary hyperhidrosis: a randomized control trial. J Am Acad Dermatol. 2013;69(1):88–95.
   PubMed Web of Science ®Google Scholar
• Lowe NJ, Yamauchi PS, Lask GP, et al. Efficacy and safety of botulinum toxin type A in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. Dermatol Surg. 2002;28(9):822–827.
   PubMed Web of Science ®Google Scholar
• Naver H, Swartling C, Aquilonius SM. Palmar and axillary hyperhidrosis treated with botulinum toxin: one-year clinical follow-up. Eur J Neurol. 2000;7(1):55–62.
   PubMed Web of Science ®Google Scholar
• Schnider P, Binder M, Auff E, et al. Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol. 1997;136(4):548–552.
   PubMed Web of Science ®Google Scholar
• Yamashita N, Shimizu H, Kawada M, et al. Local injection of botulinum toxin A for palmar hyperhidrosis: usefulness and efficacy in relation to severity. J Dermatol. 2008;35(6):325–329.
   PubMed Web of Science ®Google Scholar
• Bechara FG, Georgas D, Sand M, et al. Effects of a long-pulsed 800-nm diode laser on axillary hyperhidrosis: a randomized controlled half-side comparison study. Dermatol Surg. 2012;38(5):736–740.
   PubMed Web of Science ®Google Scholar
• Fatemi Naeini F, Abtahi-Naeini B, Pourazizi M, et al. Fractionated microneedle radiofrequency for treatment of primary axillary hyperhidrosis: a sham control study. Australas J Dermatol. 2015;56(4):279–284.
   PubMed Web of Science ®Google Scholar
• Nestor MS, Park H. Safety and efficacy of micro-focused ultrasound plus visualization for the treatment of axillary hyperhidrosis. J Clin Aesthet Dermatol. 2014;7(4):14–21.
   PubMedGoogle Scholar
• Tronstad C, Helsing P, Tonseth KA, et al. Tumescent suction curettage vs. curettage only for treatment of axillary hyperhidrosis evaluated by subjective and new objective methods. Acta Derm Venereol. 2014;94(2):215–220.
   PubMed Web of Science ®Google Scholar
• Suh DH, Lee SJ, Kim K, et al. Transient median and ulnar neuropathy associated with a microwave device for treating axillary hyperhidrosis. Dermatol Surg. 2014;40(4):482–485.
   PubMed Web of Science ®Google Scholar
• Chang CK, Chen CY, Hsu KF, et al. Brachial plexus injury after microwave-based treatment for axillary hyperhidrosis and osmidrosis. J Cosmet Laser Ther. 2017;19(7):439–441.
   PubMed Web of Science ®Google Scholar
• Stolman LP. Treatment of excess sweating of the palms by iontophoresis. Arch Dermatol. 1987;123(7):893–896.
   PubMedGoogle Scholar
• Dahl JC, Glent-Madsen L. Treatment of hyperhidrosis manuum by tap water iontophoresis. Acta Derm Venereol. 1989;69(4):346–348.
   PubMed Web of Science ®Google Scholar
• Karakoc Y, Aydemir EH, Kalkan MT. Placebo-controlled evaluation of direct electrical current administration for palmoplantar hyperhidrosis. Int J Dermatol. 2004;43(7):503–505.
   PubMed Web of Science ®Google Scholar
• Kim DH, Kim TH, Lee SH, et al. Treatment of palmar hyperhidrosis with tap water iontophoresis: a randomized, sham-controlled, single-blind, and parallel-designed clinical trial. Ann Dermatol. 2017;29(6):728–734.
   PubMed Web of Science ®Google Scholar
• Na GY, Park BC, Lee WJ, et al. Control of palmar hyperhidrosis with a new "dry-type" iontophoretic device. Dermatol Surg. 2007;33(1):57–61.
   PubMed Web of Science ®Google Scholar
• Choi YH, Lee SJ, Kim DW, et al. Open clinical trial for evaluation of efficacy and safety of a portable "dry-type" iontophoretic device in treatment of palmar hyperhidrosis. Dermatol Surg. 2013;39(4):578–583.
   PubMed Web of Science ®Google Scholar
• Dechartres A, Trinquart L, Boutron I, et al. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ. 2013;346(14):f2304.
   PubMedGoogle Scholar
• Holzle E, Braun-Falco O. Structural changes in axillary eccrine glands following long-term treatment with aluminium chloride hexahydrate solution. Br J Dermatol. 1984;110(4):399–403.
   PubMed Web of Science ®Google Scholar
• Brackenrich J, Fagg C. Hyperhidrosis. Treasure Island (FL): StatPearls; 2020.
   Google Scholar
• Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–407.
   PubMed Web of Science ®Google Scholar
• Grunfeld A, Murray CA, Solish N. Botulinum toxin for hyperhidrosis: a review. Am J Clin Dermatol. 2009;10(2):87–102.
   PubMed Web of Science ®Google Scholar
• Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352(9128):609–613.
   PubMed Web of Science ®Google Scholar
• Poolman RW, Struijs PA, Krips R, et al. Reporting of outcomes in orthopaedic randomized trials: does blinding of outcome assessors matter? J Bone Joint Surg Am. 2007;89(3):550–558.
   PubMed Web of Science ®Google Scholar
• Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273(5):408–412.
   PubMed Web of Science ®Google Scholar
• Elwyn G, Frosch D, Thomson R, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27(10):1361–1367.
   PubMed Web of Science ®Google Scholar
• Makoul G, Clayman ML. An integrative model of shared decision making in medical encounters. Patient Educ Couns. 2006;60(3):301–312.
   PubMed Web of Science ®Google Scholar